1-3 of 3
N. Cascavilla
Close
Sort by
Journal Articles

90 y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group

A. M. Carella, S. Nati, G. Fraternali Orcioni, M. Petrini, S. Galimberti, U. Vitolo, N. Cascavilla, P.L. Zinzani
Journal: Blood
Blood (2008) 112 (11): 3061.
https://doi.org/10.1182/blood.V112.11.3061.3061
Published: 2008
Journal Articles

Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.

Potito Rosario Scalzulli, MD, Maria Rosa Valvano, SD, Carlo C. Bodenizza, MD, Angelo Michele Carella, MD, Matteo M. Dell’Olio, MD, Antonietta A.P. Falcone, MD, Michele Mario Greco, MD, Antonio A. La Sala, MD, Francesco F.S. Mantuano, MD, Lorella L. Melillo, MD, Emanuela E. Merla, MD, Michele M. Nobile, MD, Sanpaolo G. Sanpaolo, MD, Nicola N. Cascavilla, MD
Journal: Blood
Blood (2007) 110 (11): 5117.
https://doi.org/10.1182/blood.V110.11.5117.5117
Published: 2007
Journal Articles

Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.

A.M. Carella, MD, M. Spriano, MD, M. T. Corsetti, MD, P. Scalzulli, MD, G. Beltrami, MD, E. Lerma, MD, PhD, N. Cascavilla, MD, M. Carella, MD, S. Nati, MD, A. Congiu, MD, P. Musto, MD
Journal: Blood
Blood (2005) 106 (11): 1126.
https://doi.org/10.1182/blood.V106.11.1126.1126
Published: 2005